What is it about?

We studied if a type of medication called SGLT2i increases the risk of urinary or genital infections in persons with type 2 diabetes compared to another medication, GLP-1RAs. We found that SGLT2is do not increase the risk of urinary infections but do have a higher risk of genital infections.

Featured Image

Read the Original

This page is a summary of: Risk of Urogenital Infections in People With Type 2 Diabetes Initiating SGLT2i Versus GLP-1RA in Routine Clinical Care: A Danish Cohort Study, Diabetes Care, April 2025, American Diabetes Association,
DOI: 10.2337/dc24-2169.
You can read the full text:

Read

Contributors

The following have contributed to this page